# US 2021/0330713 A1 · Human hepatocytes and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330713 A1
- Document ID: US20210330713A1
- Status: Published application
- Kind: A1
- Application number: 17/244,644
- Filed: 2021-04-29
- Published: 2021-10-28
- Earliest claimed: 2014-11-26
- Assignees: Accelerated Biosciences Corp.
- Applicants: Accelerated Biosciences Corp.
- Inventors: Jau-Nan LEE; Tony Tung-Yin LEE; Yuta LEE; Eing-Mei TSAI
- Web page: https://patentgrep.com/patent/US20210330713A1

## CPC

- A61K 35/407: Liver; Hepatocytes
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- C12N 5/067: {Hepatocytes}
- C12N 5/0671: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/20: Cytokines; Chemokines
- C12N 2501/237: Oncostatin M [OSM]
- C12N 2501/39: Steroid hormones
- C12N 2501/40: Regulators of development
- C12N 2501/65: MicroRNA
- C12N 2506/025: from extra-embryonic cells, e.g. trophoblast, placenta
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are human hepatocytes for example isolated human hepatic progenitor cells, artificial tissue or organ thereof, and kits or compositions thereof. Also disclosed herein are various methods of using a human hepatocyte disclosed herein.

## Claims

### Claim at position 1

1-89. (canceled)

### Claim 90

An isolated human hepatocyte, wherein the isolated human hepatocyte endogenously expresses transforming growth factor beta 1 (TGFβ1), fibronectin, and collagen IV.

### Claim 91 (depends on 90)

The isolated human hepatocyte of claim 90, wherein the isolated human hepatocyte is a human hepatic progenitor cell.

### Claim 92 (depends on 90)

The isolated human hepatocyte of claim 90, wherein the isolated human hepatocyte further expresses human leukocyte antigen G (HLA-G).

### Claim 93 (depends on 90)

The isolated human hepatocyte of claim 90, wherein the isolated human hepatocyte recruits CD4+Foxp3+Treg cells.

### Claim 94 (depends on 90)

The isolated human hepatocyte of claim 90, wherein a plurality of the isolated human hepatocytes is present in a cluster or an aggregate.

### Claim 95 (depends on 90)

The isolated human hepatocyte of claim 90, wherein a plurality of the isolated human hepatocytes forms a tissue of a 3-dimensional structure.

### Claim 96 (depends on 90)

The isolated human hepatocyte of claim 90, wherein a plurality of the isolated human hepatocytes forms a crescent cell mass.

### Claim 97 (depends on 90)

A kit comprising the isolated human hepatocyte of claim 90 and a carrier.

### Claim 98 (depends on 90)

A pharmaceutical composition comprising the isolated human hepatocyte of claim 90 and a pharmaceutically acceptable carrier.

### Claim 99 (depends on 98)

A method of treating a disorder of liver tissue or liver function in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of claim 98, whereby the disorder is treated.

### Claim 100 (depends on 90)

A method of screening a therapeutic compound for use in treatment or prevention of a condition, comprising:
a) contacting the isolated human hepatocyte of claim 90, with the therapeutic compound; and
b) detecting an expression level of a biomarker in the isolated human hepatocyte.

### Claim 101 (depends on 90)

A method of producing a therapeutic protein, comprising culturing the isolated human hepatocyte of claim 90 in a medium and extracting the therapeutic protein from the medium.

### Claim 102 (depends on 90)

A method of regenerating a liver, comprising applying the isolated human hepatocyte of claim 90 to an ex vivo perfusion system to regenerate the liver.

### Claim 103 (depends on 90)

A cell therapy, comprising intravenously administering to a subject in need thereof a composition that comprises the isolated human hepatocyte of claim 90.

### Claim 104 (depends on 90)

A method of bioprinting, comprising applying the isolated human hepatocyte of claim 90 to a bioprinting system.

### Claim 105 (depends on 90)

A method of generating a tissue scaffold, comprising culturing the isolated human hepatocyte of claim 90 in a medium on a three-dimensional biocompatible substrate to generate the tissue scaffold.

### Claim 106

An artificial tissue or organ, comprising human hepatocytes that express alpha-1-fetoprotein (AFP), albumin (ALB), alpha-1-antitrypsin, glucose, or glycogen.

### Claim 107

An artificial tissue or organ, comprising human hepatocytes that endogenously express human leukocyte antigen G (HLA-G) and one or more biomarkers from C-X-C chemokine receptor type 4 (CXCR4), forkhead box protein A2 (FOXA2), hematopoietically expressed homeobox (HHEX), cytochrome P450 7A1 (CYP7A1), bile salt export pump (BSEP), alpha-1-antitrypsin member 1 (SERPINA1), ATP-binding cassette sub-family C member 2 (ABCC2), CCAAT-enhancer-binding protein beta (C/EBPβ), hepatocyte nuclear factor 1-alpha (HNF1α), or any combination thereof.